PAREXEL Experts to Share Key Industry Insights at DIA 2013 49th Annual Meeting
Boston, MA, June 19, 2013 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that several of its experts will present on timely industry issues at the 49th Drug Information Association (DIA) Annual Meeting, taking place June 23-27, 2013 in Boston.
As one of the top clinical research organizations (CROs) serving the pharmaceutical and biopharmaceutical industries, PAREXEL is in a unique position to address changes reshaping the clinical research market. At DIA, the company’s experts will discuss how biopharmaceutical companies can navigate the challenging regulatory and commercial environment to seize opportunities for growth and success. Session topics range from Japan regulatory considerations and industry legislation to orphan drugs, strategic partnerships and clinical trials technology.
“We believe we are in the midst of an industry transformation,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “Research and innovation are paramount to successfully navigating these changes. PAREXEL and DIA continue to work toward the common goal of enabling channels for greater cooperation and effectiveness in clinical research.”
The following sessions include a sampling of topics that will be discussed by various PAREXEL experts during the program.
Sunday, June 23
- 8:30 a.m.: (Track 8 – Regulatory Affairs and Submissions) “Japan Regulatory Environment: Overview of the Organization, Processes, Systems, and Changes Affecting Pharmaceutical Developments,” Alberto Grignolo, PhD, Corporate Vice President, Global Strategy and Services
Monday, June 24
- 11:00 a.m.: (Track 1– Clinical Operations) “Trials, Studies and Programs: Diverse Operational Approaches to Generating Evidence in the Late-phase Environment,” Gary Coward, Global Head, Patient Safety Services
Tuesday, June 25
- 1:45 p.m.: (Track 6 – Medical Communication, Medical Writing and Medical Science Liaison) “The New European Pharmacovigilance Legislation: Guiding Medical Writers Through Risks and Benefits,” Julia Cooper, Senior Director, Worldwide Head of Medical Writing Services
- 1:45 p.m.: (Track 3 – Innovative Partnering Models and Outsourcing Strategies) “Pharma, Academia and CRO Preferred Partnerships: Why Collaboration Makes a Better Global Trial,” Sara Tullberg, PhD, Senior Project Leader
Wednesday, June 26
- 1:45 p.m.: (Track 17– Rare/Orphan Diseases) “Rising to the Challenge of Developing Novel Orphan Medicines for the Global Market,” Cecil J. Nick, B.Sc. (Hons), FTOPRA, Vice President, Technical, PAREXEL Consulting
Thursday, June 27
- 9:00 a.m.: (Track 17– Rare/Orphan Diseases) “The Not So Rare Challenge that Faces Rare Disease Development: Demonstrate Value,” Charles A. Stevens, JD, MBA, Vice President and General Manager, Commercialization Strategy
The full list of PAREXEL speakers and session topics can be found here.
For more information about PAREXEL, visit www.PAREXEL.com or Booth #215 during the meeting. Information about DIA 2013 can be found at http://www.diahome.org/en/Flagship-Meetings/DIA2013.aspx.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based clinical research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 78 locations throughout 52 countries around the world, and has approximately 14,400 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 as filed with the SEC on May 6, 2013, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.